A Randomized Study of Low-Dose Interleukin-2 Subcutaneous Immunotherapy versus Interleukin-2 plus Interferon-Alpha as First Line Therapy for Metastatic Renal Cell Carcinoma - Concepedia

Concepedia

Publication | Closed Access

A Randomized Study of Low-Dose Interleukin-2 Subcutaneous Immunotherapy versus Interleukin-2 plus Interferon-Alpha as First Line Therapy for Metastatic Renal Cell Carcinoma

30

Citations

5

References

1993

Year

Paolo Lissoni, Sandro Barni, Antonio Ardizzoia, Marco Andres, E. Scardino, P Cardellini, Ruggero Della Bitta, Gabriele Tancini

Abstract

The present results, which require confirmation in a larger series, indicate that combination with IFN does not increase the efficacy of IL-2 subcutaneous immunotherapy in metastatic RCC but only the toxicity of treatment.

References

	Year	Citations

Page 1